| 1 |
NCT00365716 |
Completed
Has Results |
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) |
- Papillomavirus Infections
- Genital Diseases, Female
|
- Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
- Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40
- Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
- (and 2 more...)
|
Interventional |
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Number of Subjects With Injection Site Adverse Experiences
- Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)
|
1158 |
Female |
16 Years to 23 Years (Child, Adult) |
NCT00365716 |
V501-007
2006_516 |
|
May 2000 |
May 2004 |
September 2009 |
August 17, 2006 |
October 7, 2015 |
August 3, 2010 |
|
| 2 |
NCT02503111 |
Enrolling by invitation |
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men |
- Anal Dysplasia
- Human Papillomavirus
- Anal Cancer
|
- Device: The Hyfrecator ® 2000 Electrosurgical System
- Other: Observation Alone
|
Interventional |
Not Applicable |
- University Health Network, Toronto
- Canadian Institutes of Health Research (CIHR)
- Ontario HIV Treatment Network
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Anal dysplasia treatment on a per-patient basis
- Resolution of high-grade AIN at 3 and 6 months on a per-lesion basis
- Acceptance rate of participants recruited into the study
- (and 2 more...)
|
3000 |
Male |
18 Years and older (Adult, Senior) |
NCT02503111 |
HPV-SAVE |
HPV-SAVE |
November 2015 |
November 2020 |
December 2020 |
July 20, 2015 |
September 15, 2016 |
|
- BC Centre for Disease Control
Vancouver, British Columbia, Canada - University of British Columbia
Vancouver, British Columbia, Canada - Ottawa Hospital Research Institute
Ottawa, Ontario, Canada - University Health Network - Toronto General Hospital
Toronto, Ontario, Canada
|
| 3 |
NCT02276521 |
Completed |
Evaluation of Long Term Immunity Following HPV Vaccination |
- Cervical Cancer
- Anogenital Warts
|
|
Observational |
|
- Murdoch Childrens Research Institute
- Department of Foregin Affairs and Trade, Australia
- Ministry of Health, Fiji
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- GMCs of HPV- specific antibody titres against HPV 6, 11, 16 and 18
- GMCs of HPV- specific antibody titres against HPV 6, 11, 16 and 18 one month post Cervarix®
- Number of HPV- specific memory B- and T- cells against HPV 6, 11, 16 and 18 pre and one month post Cervarix®
- Fold change in the gene expression profiles in immune cells both pre- and one month post Cervarix®
|
200 |
Female |
15 Years to 17 Years (Child) |
NCT02276521 |
2014.5.FNRERC.5.SU |
|
February 2015 |
March 2015 |
March 2015 |
October 28, 2014 |
September 23, 2015 |
|
- Colonial War Memorial Hospital
Suva, Fiji
|
| 4 |
NCT00666107 |
Unknown † |
Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men |
- Anal Cancer
- HIV Infections
|
|
Interventional |
Not Applicable |
- Southern California Institute for Research and Education
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Determine Geometric Mean Titers of anti-HPV 16 and anti-HPV 18 antibodies
- Determine percentage of subjects who seroconverted or mounted a significant serologic response to each of the 2 antigens 16 and 18
- Determine how many patients, if any, develop evidence of anal HPV infection, as measured by development of a positive HPV test.
- Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit
|
150 |
Male |
18 Years and older (Adult, Senior) |
NCT00666107 |
#33245 |
MIRB #862 |
June 2008 |
June 2012 |
June 2012 |
April 24, 2008 |
March 14, 2012 |
|
- VA Long Beach Healthcare System
Long Beach, California, United States
|
| 5 |
NCT01687192 |
Unknown † |
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. |
- Transplantation
- Systemic Lupus Erythematosus
- Systemic Immune Disease
|
- Biological: HPV prophylactic vaccine Gardasil
|
Interventional |
Phase 2 |
- University Hospital, Bordeaux
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Seroconversion rate for HPV 16 and 18 at M18
- Geometric means of anti-HPV 6, 11, 16 and 18 antibody titers at M7, M18, and M36, respectively.
- Proportion of patients with a good cell response at M7 and M18
- (and 2 more...)
|
37 |
Female |
9 Years to 18 Years (Child, Adult) |
NCT01687192 |
CHUBX 2011/18 |
PRIMAVERA |
October 2012 |
May 2015 |
November 2016 |
September 18, 2012 |
July 31, 2015 |
|
- CHU de Bordeaux, Hôpital Pellegrin-Enfants
Bordeaux, France - HCLyon, Hôpital Femme-mère-enfant
Bron, France - CHU de Lille, Hôpital Jeanne de Flandres
Lille, France - (and 6 more...)
|
| 6 |
NCT00941889 |
Completed
Has Results |
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata |
- HIV Positive
- Anal Condylomata
- Anal Warts
- HIV Infections
|
- Drug: Saline
- Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
|
Interventional |
Not Applicable |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups.
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT00941889 |
HRPO 07-0648 |
|
July 2007 |
July 2011 |
July 2011 |
July 20, 2009 |
July 25, 2016 |
July 25, 2016 |
- Washington University in St. Louis, Section of Colon Rectal Surgery
St. Louis, Missouri, United States
|
| 7 |
NCT00730704 |
Completed |
Acceptance of Human Papillomavirus Vaccination in Postpartum Women |
- Human Papilloma Virus
- HPV
- Post Partum
|
|
Observational |
|
- Columbia University
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
150 |
Female |
18 Years to 26 Years (Adult) |
NCT00730704 |
AAAD1877 |
HPV Acceptance |
May 2009 |
October 2012 |
October 2012 |
August 8, 2008 |
November 5, 2012 |
|
- Columbia University Medical Center
New York, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: